Gossamer Bio, Inc. (GOSS) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. Today's conference call is scheduled to begin momentarily. Please continue to stand by. Thank you for patience. Once again, today's conference call is scheduled to begin momentarily. Please continue to stand by. Thank you for patience. Thank you. Thank you. Good day and thank you for standing by. Welcome to the Gossamer Bio Q4 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone keypad. And if you require any further assistance, you may press star 0. Without further ado, I would like to welcome your first speaker for today, Mr. Brian Dorado, sir, the floor is yours. Thank you, operator, and thank you all for joining us this afternoon. I am joined on today's call by Gossamer's co-founder, chairman, and chief executive officer, Fahim Hasning, Gossamer's chief medical officer, Dr. Richard Aranda, and Gossamer's chief scientific officer, Dr. Laura Carter. Earlier today, Gossamer issued a press release announcing its year-end 2021 financial results and provided a corporate update. Please note that certain information discussed on the call is covered under the safe harbor vision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Gossamer Management will be making forward-looking statements. Actual results may differ materially from those that are implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the statements contained in Gossamer's news releases, SEC filings, including in the annual report on Form 10-K and substance vio...